Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 5
Submit an article Journal homepage
535
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin

Evaluation of Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-158

Thomas BlevinsTexas Diabetes & Endocrinology, P.A, 6500 N MoPac Expwy, Building III, Suite 200, Austin, TX 78731, USA+1 512 458 8400; [email protected]
, MD
Pages 789-793 | Published online: 19 Mar 2015

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Brian Tomlinson, Paul Chan & Christopher Wai Kei Lam. (2022) An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:1, pages 29-42.
Read now

Articles from other publishers (4)

Ankit Gupta, Sheenu Mittal, Monika, Richa Dhingra & Neelima Dhingra. (2020) Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life. Current Diabetes Reviews 16:7, pages 716-732.
Crossref
Yingying Yang, Shi Chen, Hui Pan, Yun Zou, Bo Wang, Guixia Wang & Huijuan Zhu. (2017) Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes. Medicine 96:21, pages e6944.
Crossref
Hermann Koepsell. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & Therapeutics 170, pages 148-165.
Crossref
Muhammad A. Abdul-Ghani, Luke Norton & Ralph A. DeFronzo. (2015) Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. American Journal of Physiology-Renal Physiology 309:11, pages F889-F900.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.